Director dealings: Syncona non-executive director snaps up shares
22nd Jun 2026 13:46
(Sharecast News) - Syncona revealed on Monday that non-executive director John Roche had acquired 16,063 ordinary shares in the FTSE 250-listed healthcare investor.
Read moreSyncona reports broadly stable net asset value
18th Jun 2026 11:16
(Sharecast News) - Syncona reported broadly stable net asset value for the year ended 31 March on Thursday, as gains at Beacon Therapeutics offset weakness elsewhere in its life sciences portfolio, while the healthcare investor reiterated plans to return at least £250m to shareholders.
Read moreLondon close: Stocks lower as BoE keeps rates on hold
19th Jun 2025 16:23
(Sharecast News) - London equities ended lower on Thursday after the Bank of England left interest rates unchanged, in line with market expectations.
Read moreSyncona announces strategic pivot after board review
19th Jun 2025 11:20
(Sharecast News) - Syncona announced a strategic pivot toward an orderly realisation of its portfolio assets on Thursday, as the life sciences investor looked to balance returning cash to shareholders with efforts to maximise long-term value from its maturing holdings.
Read moreSyncona firm Beacon reports encouraging gene therapy trial results
7th May 2025 11:36
(Sharecast News) - Syncona said in an update on Wednesday that its portfolio company Beacon Therapeutics has reported encouraging six-month interim results from its phase two 'DAWN' trial, marking a key milestone in the development of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP).
Read moreLondon close: Stocks mixed in quiet post-Christmas trade
27th Dec 2024 14:38
(Sharecast News) - London markets closed on a mixed note Friday in subdued trading, as the ongoing holiday period kept activity light with little news to influence sentiment.
Read moreSyncona investment sells cancer study assets to AstraZeneca for $12m
27th Dec 2024 07:03
(Sharecast News) - Life science investor Syncona said its investment Achilles Therapeutics has sold cancer study assets to AstraZeneca for $12m (£9.58m).
Read moreSyncona upbeat on interim trial results at Beacon Therapeutics
6th Dec 2024 14:55
(Sharecast News) - Syncona announced positive three-month interim results from the phase two 'DAWN' trial conducted by its portfolio company Beacon Therapeutics on Friday.
Read moreSyncona launches Slingshot platform with £12.5m investment
14th Nov 2024 11:34
(Sharecast News) - Syncona announced the launch of Slingshot Therapeutics, a new portfolio company and accelerator dedicated to developing early-stage life science programs sourced from academia, on Thursday.
Read moreSyncona's Autolus gets FDA approval for leukaemia treatment
11th Nov 2024 07:17
(Sharecast News) - Life science investor Syncona announced on Monday that its portfolio company Autolus Therapeutics has received US Food and Drug Administration (FDA) approval for Aucatzyl (obe-cel), a CAR T-cell therapy developed for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).
Read moreSyncona's Purespring raises £80m in new financing
9th Oct 2024 07:21
(Sharecast News) - Life science investor Syncona said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseases, had raised £80m in an oversubscribed financing.
Read moreSyncona commits £63.5m to Resolution Therapies
3rd Oct 2024 12:14
(Sharecast News) - Syncona announced on Thursday that it has committed £63.5m in series B financing to Resolution Therapeutics, a portfolio company focused on macrophage therapy for inflammatory and fibrotic diseases.
Read moreSyncona confident in portfolio despite fall in NAV
13th Aug 2024 11:57
(Sharecast News) - Life science investor Syncona reported significant developments in its portfolio during its first quarter on Tuesday, despite a slight decline in net assets.
Read moreSyncona adds two oncology investments to portfolio
20th Jun 2024 12:11
(Sharecast News) - Life science investor Syncona announced the addition of two new oncology companies to its portfolio on Thursday.
Read moreSyncona reports positive findings from investee Freeline
9th May 2024 11:19
(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.
Read more